CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Aclaris Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Aclaris Therapeutics Inc
701 Lee Road, Suite 103
Phone: (302) 658-7581p:302 658-7581 WAYNE, PA  19087  United States Ticker: ACRSACRS
Business Summary
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small and large molecule product candidates for immuno-inflammatory diseases. Its proprietary KINect drug discovery platform coupled with its integrated discovery approach to small and large molecules enables the Company to identify and advance product candidates. It provides contract research services to third parties enabled by its early-stage research and development expertise. The contract research segment is engaged in the provision of laboratory services. Its product candidate pipeline includes Bosakitug (ATI-045), ATI-2138 and ATI-052. The Bosakitug (ATI-045) is an investigational, novel, humanized anti-Thymic stromal lymphopoietin (TSLP) monoclonal antibody that specifically binds to human TSLP, blocking its interaction with the receptor complex and disrupting signal transduction. Its other investigational product candidate is Lepzacitinib (ATI-1777).
(Source: 6-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202612/31/2025YesYes--Yes

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations
2899 Chemicals and chemical preparations, not elsewhere classified
7389 Business services, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board, Chief Executive Officer, Co-Founder Neal S.Walker 55 2/1/2025 7/1/2012
President, Chief Operating Officer, Director Hugh M.Davis 66 11/18/2024 11/18/2024
Chief Financial Officer KevinBalthaser 38 1/1/2023 1/1/2023
8 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
ACLARIS THERAPEUTICS INTERNATIONAL LIMITED 3RD FLOOR 1 ASHLEY ROAD ALTRINCHAM UK
Confluence Life Sciences, Inc. 4320 Forest Park Avenue St. Louis MO United States

Business Names
Business Name
Aclaris Life Sciences, Inc.
ACRS
Confluence Discovery Technologies, Inc.

General Information
Number of Employees: 69 (As of 12/31/2025)
Outstanding Shares: 139,663,680 (As of 4/14/2026)
Shareholders: 46
Stock Exchange: NASD
Federal Tax Id: 460571712
Fax Number: (302) 655-5049
Email Address: info@vicepttx.com


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, May 12, 2026